In this study, we demonstrate that together HDAC1 and HDAC2 activities are responsible for the decreased expression of BRCA1, CHK1, and RAD51 following class I- or pan-HDACI treatment in AML cells. This evidence concerns the gene HDAC2 and acute myeloid leukemia.